Rat Models of Retinal Vein Occlusion in the MICRON Literature

About the MICRON Research Literature

These research pages organize published studies using MICRON imaging systems by animal species and the disease or condition investigated.

All publication counts and figures reflect the complete indexed research collection.

Explore related studies through the MICRON Research Hubs or search the complete publication collection in the reSEARCH portal.

Understanding Retinal Vein Occlusion

Retinal vein occlusion is an obstruction of venous outflow from the retina, usually understood as a thrombotic event arising in a vascular setting shaped by local anatomy and systemic risk factors.

The recognized contributors include:

• Age
• Hypertension
• Hyperlipidemia
• Diabetes
• Raised intraocular pressure
• Hyperviscous or thrombophilic states

Obstructed outflow raises pressure upstream of the blockage and produces intraretinal hemorrhage, retinal edema, capillary non-perfusion and, where non-perfusion is extensive, ischemia-driven new vessel growth.

Retinal Vein Occlusion in Experimental Research

Rodent work reaches that state by a different route: a widely used approach gives a photosensitizing dye intravenously and applies laser to a chosen retinal vein, placing an occlusion at a known vessel within minutes, and genetic and pharmacological routes to retinal thrombosis are also described. That laser preparation can be run in a young animal with no antecedent vascular disease.

What such a model supplies is an occlusion of known onset and location, so the sequence from obstruction through edema, inner retinal cell loss and inflammatory response can be followed from its beginning and an intervention timed against it.

What the laser preparation does not supply is the antecedent:

• Where the occlusion is placed in a vessel that was healthy beforehand, the aging, hypertensive or hyperviscous vasculature in which a human occlusion develops is absent by construction
• Such an occlusion can reperfuse within days, so a long-standing obstruction is harder to sustain than in patients

A model built instead on a genetic or metabolic predisposition to thrombosis carries an antecedent of its own, and what it carries is the predisposition engineered into it rather than the accumulated vascular and systemic disease of a patient. Vision loss in human retinal vein occlusion is driven largely by macular edema, and mouse and rat retinas have no macula, so swelling here is assessed as thickening of the affected retinal sector rather than as the macular endpoint that governs human acuity.

Rat Models of Retinal Vein Occlusion

The rat offers a larger eye than the mouse while remaining a small-animal model, which eases injection and imaging without moving to a large species.

Published MICRON Research: Retinal Vein Occlusion in Rats

This page lists 3 papers from the MICRON literature, published 2019 to 2024, that study retinal vein occlusion in rats.

Of these publications:

• 3 studies used rats as the primary retinal vein occlusion disease model.

Scope of the literature collection: Publication counts reflect studies identified and indexed in the MICRON research corpus. This collection is not intended to represent an exhaustive review of all published retinal vein occlusion research.

Which imaging and experimental techniques are used in these studies?

Technique counts are paper-level co-occurrences and do not necessarily indicate that a technique was applied to the focal species or focal disease model.

Capabilities and Limitations of Imaging Techniques

A summary of what each imaging technique listed above can measure, the information it provides, and its limitations in research applications.

Intravitreal Injection / Delivery

Injection into the vitreous places a substance directly into the vitreous at a known administered dose and chosen time, reducing but not eliminating systemic exposure. The injectate may be a therapeutic compound, cell preparation or viral vector, or an agent used to create the model, such as a toxin, vasoactive or excitotoxic compound, or infectious inoculum. The route bypasses surface-delivery barriers and provides direct access to the vitreous and posterior segment, but the concentration reached in a particular ocular tissue depends on distribution and clearance and is not fixed by the injected dose alone. It is invasive and discrete: each repeat dose or challenge requires another injection, and vehicle- or sham-injected controls can help separate effects of the injectate from effects of the procedure.

Electroretinography

Records the retina's electrical response to light, giving component-sensitive information about outer- and inner-retinal function. It measures function directly, which no structural method does. Full-field ERG sums across the whole retina, so a small lesion can leave the trace unchanged; focal and multifocal variants trade signal amplitude for spatial resolution.

Laser Photocoagulation Models

A laser lesion provokes a reproducible, quantifiable injury at a known time and place. Wavelength, power, duration, spot size, pulse mode, focus and lesion location together determine the injury produced, allowing laser exposure to be configured for different experimental endpoints. In retinal vascular occlusion work the laser is a means of occluding a chosen retinal vessel, by photothrombosis after a photosensitiser has been given systemically or by direct photocoagulation of the vessel. The occlusion is the placed event, and much of the subsequent edema, ischemia, inner-retinal cell loss and inflammatory response arises downstream from impaired perfusion rather than from direct destruction of the whole affected retinal territory, although the laser can cause focal collateral injury at the target vessel. What such a preparation does not necessarily supply is the clinical antecedent that produced the occlusion: for example chronic local or systemic vascular disease, an arteriovenous-crossing lesion in branch vein occlusion, or an embolic or arteritic source in arterial occlusion. It therefore models the vascular obstruction and its retinal consequences more directly than it models the disease process that caused the obstruction in a patient.

Topical Ophthalmic Drug Delivery

A compound applied as drops to the ocular surface. It is non-invasive and repeatable, so it supports frequent dosing without a procedure for each dose. What the route has to establish depends on the target: for an ocular-surface target, residence time and penetration into the surface tissue are the main barriers; for an intraocular anterior-segment target, the compound must cross ocular-surface and corneal or conjunctival barriers and reach an intraocular concentration sufficient for the experiment; for a posterior-segment target, additional ocular barriers separate the surface from the target and posterior-segment exposure is harder to establish.

Which MICRON systems and add-ons appear?

Which strains and genetic lines are used?

Which MICRON configurations appear in this work?

Configurations recorded in these papers, and the techniques recorded alongside them.

The papers

Browse all hubs at MICRON Research Hubs. The full corpus is searchable in the reSEARCH portal.